Pluristem Therapeutics to Host Key Opinion Leader Call on Its Acute Radiation Syndrome and Hematological Programs
Data readout from second cohort of hematological study will be presented Call scheduled for Monday, September 16 at 10:00am ET
HAIFA, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) -- (PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced additional information relating to its live Key Opinion Leader (KOL) call regarding its hematological programs on September 16, 2019.
The call will feature presentations by Jacob M. Rowe, MD and Bert. W. Maidment, Ph.D, and will include discussions regarding the findings from Pluristem’s ongoing clinical study in hematological deficiencies, as well as opportunities and future product development. In addition, Pluristem’s management will review the status of the company’s radiation programs with the U.S government, including an overview of recent Department of Defense (DoD) data, potential markets and expected milestones.
Jacob M. Rowe, MD is chief of the Department of Hematology and The Ann and Pinky Sohn Chair in Hemato-Oncology at the Shaare Zedek Medical Center in Jerusalem, and Emeritus Professor at the Technion, Israel Institute of Technology in Haifa. Dr. Rowe has actively participated in a wide range of national and international research projects and initiatives. He is a former chairman of the Leukemia Committee of the Eastern Cooperative Oncology Group (ECOG) and has developed and chaired many Phase II and III studies on leukemia, lymphoma, and bone marrow transplantation. Dr. Rowe is also an Adjunct Professor at the Department of Medicine of Northwestern University, Chicago, IL. He has received many prestigious awards, including an honorary doctorate from the University of Gothenburg in Sweden, has published over 500 peer-reviewed articles, reviews and book chapters and is a frequent invited speaker or chairman at international meetings.
Bert. W. Maidment, Ph.D., is the Executive Consultant and former Associate Director for Radiation Countermeasures Research and Emergency Preparedness at the National Institutes of Health, NIAID/DAIT/Radiation Nuclear Countermeasures Program.
Monday, September 16th at 10am Eastern/7am Pacific
Domestic: 800-479-1004
International: 323-794-2597
Conference ID: 4428235
Webcast:
For those who are unable to listen at this time, a replay of the call will be available by clicking .
About Pluristem Therapeutics
Pluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, ischemia, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Company's proprietary three-dimensional expansion technology and can be administered to patients off-the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a Company-owned and operated GMP-certified manufacturing and research facility; strategic relationships with major research institutions; and a seasoned management team.
Safe Harbor Statement
This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluristem is using forward-looking statements when it discusses the topics that will be discussed on the KOL call. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; Pluristem may encounter delays or obstacles in launching and/or successfully completing its clinical trials; Pluristem’s products may not be approved by regulatory agencies, Pluristem’s technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; Pluristem may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with Pluristem’s process; Pluristem’s products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; Pluristem’s patents may not be sufficient; Pluristem’s products may harm recipients; changes in legislation may adversely impact Pluristem; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.
Contact:
Efrat Kaduri
Director of Business, Investor and Public Relations
972-74-7108600
